Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications.

BMC Cancer 2013 Jun 3;13:271. Epub 2013 Jun 3.

Department of Obstetrics and Gynecology, University Hospital Freiburg, Freiburg 79106, Germany.

Background: Cancer-testis antigens (CTA) comprise a family of proteins, which are physiologically expressed in adult human tissues solely in testicular germ cells and occasionally placenta. However, CTA expression has been reported in various malignancies. CTAs have been identified by their ability to elicit autologous cellular and or serological immune responses, and are considered potential targets for cancer immunotherapy. The breast differentiation antigen NY-BR-1, expressed specifically in normal and malignant breast tissue, has also immunogenic properties. Here we evaluated the expression patterns of CTAs and NY-BR-1 in breast cancer in correlation to clinico-pathological parameters in order to determine their possible impact as prognostic factors.

Methods: The reactivity pattern of various mAbs (6C1, MA454, M3H67, 57B, E978, GAGE #26 and NY-BR-1 #5) were assessed by immunohistochemistry in a tissue micro array series of 210 randomly selected primary invasive breast cancers in order to study the diversity of different CTAs (e.g. MAGE-A, NY-ESO-1, GAGE) and NY-BR-1. These expression data were correlated to clinico-pathological parameters and outcome data including disease-free and overall survival.

Results: Expression of at least one CTA was detectable in the cytoplasm of tumor cells in 37.2% of the cases. NY-BR-1 expression was found in 46.6% of tumors, respectively. Overall, CTA expression seemed to be linked to adverse prognosis and M3H67 immunoreactivity specifically was significantly correlated to shorter overall and disease-free survival (p=0.000 and 0.024, respectively).

Conclusions: Our findings suggest that M3H67 immunoreactivity could serve as potential prognostic marker in primary breast cancer patients. The exclusive expression of CTAs in tumor tissues as well as the frequent expression of NY-BR-1 could define new targets for specific breast cancer therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-13-271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700769PMC
June 2013
31 Reads

Publication Analysis

Top Keywords

breast cancer
16
ny-br-1 expression
12
expression
9
primary breast
8
cta expression
8
clinico-pathological parameters
8
m3h67 immunoreactivity
8
ny-br-1
7
breast
7
cancer
6
cells 372%
4
determine impact
4
impact prognostic
4
order determine
4
gage ny-br-1
4
correlation clinico-pathological
4
disease-free survival
4
parameters order
4
survival p=0000
4
factorsmethods reactivity
4

References

(Supplied by CrossRef)

E Stickeler et al.
Breast Care 2011

P van der Bruggen et al.
Science 1991

A Grigoriadis et al.
Proc Natl Acad Sci USA 2009

D Atanackovic et al.
Clin Cancer Res 2009

N Yoshida et al.
Int J Oncol 2006

OL Caballero et al.
Cancer Sci 2009

E Stockert et al.
J Exp Med 1998

J Karbach et al.
Int J Cancer 2010

G Bioley et al.
Clin Cancer Res 2009

D Valmori et al.
Proc Natl Acad Sci USA 2007

Similar Publications